September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data ...

The funds will support Anaconda's clinical development aims and the completion of its pivotal IDE study.

Anaconda Biomed recently announced a $56 million funding round to advance what it describes as next-generation, novel ...

Surmodics has acquired the business of Alta Biomed, expanding its portfolio of hemocompatible and biocompatible surface ...

Anaconda Biomed, a medical technology company developing a next-generation portfolio of novel thrombectomy catheters based on its core funnel catheter technology platform, today announced the closing ...

GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ -- Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round ...

Anaconda Biomed, a medical technology company based in Barcelona, Spain, and Marin, California, has secured $56 million in financing led by Omega Funds, with participation from new investor Spain's Co ...

- BioMed Realty Continues to Support California’s Life Science Industry Growth with $2.6 Billion Capital Commitments in Last Four Years SAN DIEGO--(BUSINESS WIRE)--BioMed Realty (“BioMed”), a leading ...

Formlabs recently introduced three healthcare-focused materials to its library: BioMed Elastic 50A Resin, BioMed Flex 80A Resin, and IBT Flex Resin. The two new BioMed materials will expand the ...

Orchestra BioMed Holdings, Inc. announced that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial (?BACKBEAT Trial?), exceeding its previously announced target of 316 randomized ...